Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

CAD may lead to an 8 percent increase in adenoma detection rate and 2 percent increase in detection rate of advanced colorectal neoplasia.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Investigators from Canada and the UK conducted a systematic review and meta-analysis to update evidence associating eradication of Helicobacter pylori with reduced gastric cancer risk.

Researchers sought to evaluate preferences related to treatment features of BCMA-directed bispecific antibodies and CAR-T therapy.

Virtual reality relaxation program can reduce pain intensity, with significant changes in brain functional connectivity patterns.

A study in patients with solid tumors found that CRBSI is significantly linked to mortality in patients with PICCs, whereas CRT and CRLC are not significant risk factors.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

Barriers contributing to underreporting of fatigue also include belief that symptom is sign disease is progressing and attempt to be a “good patient.” ...

After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.